Related references
Note: Only part of the references are listed.Moxifloxacin-Loaded Lipidic Nanoparticles for Antimicrobial Efficacy
Mohammad Darvishi et al.
CURRENT PHARMACEUTICAL DESIGN (2021)
Biological Effects of Quinolones: A Family of Broad-Spectrum Antimicrobial Agents
Ana R. Millanao et al.
MOLECULES (2021)
Moxifloxacin is a safe and effective candidate agent for tuberculosis treatment: a meta-analysis of randomized controlled trials
Mingxia Sun et al.
ANNALS OF PALLIATIVE MEDICINE (2021)
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
S. E. Dorman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates
Alicja Chrzanowska et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Conjugates of Ciprofloxacin and Levofloxacin with Cell-Penetrating Peptide Exhibit Antifungal Activity and Mammalian Cytotoxicity
Natalia Ptaszynska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Quinolones: Mechanism, Lethality and Their Contributions to Antibiotic Resistance
Natassja G. Bush et al.
MOLECULES (2020)
Repositioning of fluoroquinolones from antibiotic to anti-cancer agents: An underestimated truth
Vikas Yadav et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Changes in lipids composition and metabolism in colorectal cancer: a review
Alicja Pakiet et al.
LIPIDS IN HEALTH AND DISEASE (2019)
Quinolone antibiotics
Thu D. M. Pham et al.
MEDCHEMCOMM (2019)
Alternative antimicrobials: the properties of fatty acids and monoglycerides
Colin P. Churchward et al.
CRITICAL REVIEWS IN MICROBIOLOGY (2018)
In vitro effects of ciprofloxacin, levofloxacin and moxifloxacin on Mycobacterium tuberculosis isolates
Fethiye Ferda Yilmaz et al.
TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX (2018)
L-Serine potentiates fluoroquinolone activity against Escherichia coli by enhancing endogenous reactive oxygen species production
Xiangke Duan et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis
Tim R. Blower et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Mechanism of Quinolone Action and Resistance
Katie J. Aldred et al.
BIOCHEMISTRY (2014)
Ciprofloxacin as a prophylactic agent against prostate cancer: A two hit hypothesis
T. Kloskowski et al.
MEDICAL HYPOTHESES (2012)
An Automated Force Field Topology Builder (ATB) and Repository: Version 1.0
Alpeshkumar K. Malde et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2011)
Novel N-Linked Aminopiperidine Inhibitors of Bacterial Topoisomerase Type II: Broad-Spectrum Antibacterial Agents with Reduced hERG Activity
Folkert Reck et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Widespread Occurrence of Secondary Lipid Biosynthesis Potential in Microbial Lineages
Christine N. Shulse et al.
PLOS ONE (2011)
Inhibition of DNA Gyrase by Levofloxacin and Related Fluorine-Containing Heterocyclic Compounds
V. L. Tunitskaya et al.
ACTA NATURAE (2011)
Virtual screening with AutoDock: theory and practice
Sandro Cosconati et al.
EXPERT OPINION ON DRUG DISCOVERY (2010)
AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility
Garrett M. Morris et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2009)
Antibacterial targets in fatty acid biosynthesis
H. Tonie Wright et al.
CURRENT OPINION IN MICROBIOLOGY (2007)
Fatty acid synthesis is a target for antibacterial activity of unsaturated fatty acids
CJ Zheng et al.
FEBS LETTERS (2005)
Moxifloxacin - A review of its use in the management of bacterial infections
GM Keating et al.
DRUGS (2004)
The quinolones: decades of development and use
AM Emmerson et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Dual targeting of DNA gyrase and topoisomerase IV: Target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone
D Ince et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Oxidative stress induced by ciprofloxacin in Staphylococcus aureus
MC Becerra et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
Quinolone molecular structure-activity relationships: What we have learned about improving antimicrobial activity
LR Peterson
CLINICAL INFECTIOUS DISEASES (2001)
Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus:: Different patterns of quinolone-induced inhibition of DNA synthesis
B Fournier et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Share Paper
